InsiderTrades.com logo
Christopher G. Hayes net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Christopher Hayes Biography and Net Worth

Insider of Verrica Pharmaceuticals
Mr. Hayes has served as Verrica Pharmaceuticals’ General Counsel since September 2018, and as Chief Legal Officer since February 2020. He is also our Chief Compliance Officer and Corporate Secretary. With over 30 years of wide-ranging, substantive business and legal experience, Mr. Hayes provides critical legal guidance and effective solutions to drive Verrica on the right path forward, creating value, mitigating risk, and optimizing capabilities for all stakeholders. His extensive legal knowledge spans corporate and securities law and litigation, commercial transactions, contract administration, antitrust law and complex litigation, corporate development and governance, and labor and employment law. Mr. Hayes received a BA in Economics from Villanova University and a JD from The Catholic University of America, Columbus School of Law.

What is Christopher G. Hayes' net worth?

The estimated net worth of Christopher G. Hayes is at least $78,435.58 as of March 17th, 2025. Mr. Hayes owns 176,458 shares of Verrica Pharmaceuticals stock worth more than $78,436 as of March 26th. This net worth approximation does not reflect any other investments that Mr. Hayes may own. Additionally, Mr. Hayes receives a salary of $607,380.00 as Insider at Verrica Pharmaceuticals. Learn More about Christopher G. Hayes' net worth.

How old is Christopher G. Hayes?

Mr. Hayes is currently 60 years old. There are 2 older executives and no younger executives at Verrica Pharmaceuticals. Learn More on Christopher G. Hayes' age.

What is Christopher G. Hayes' salary?

As the Insider of Verrica Pharmaceuticals Inc., Mr. Hayes earns $607,380.00 per year. There are 2 executives that earn more than Mr. Hayes. The highest earning executive at Verrica Pharmaceuticals is Mr. Ted White, President, CEO & Director, who commands a salary of $914,680.00 per year. Learn More on Christopher G. Hayes' salary.

How do I contact Christopher G. Hayes?

The corporate mailing address for Mr. Hayes and other Verrica Pharmaceuticals executives is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. Verrica Pharmaceuticals can also be reached via phone at (434) 453-3300 and via email at info@verrica.com. Learn More on Christopher G. Hayes' contact information.

Has Christopher G. Hayes been buying or selling shares of Verrica Pharmaceuticals?

Over the course of the past ninety days, Christopher G. Hayes has sold $2,804.75 in shares of Verrica Pharmaceuticals stock. Most recently, Christopher G. Hayes sold 4,315 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $0.65, for a transaction totalling $2,804.75. Following the completion of the sale, the insider now directly owns 176,458 shares of the company's stock, valued at $114,697.70. Learn More on Christopher G. Hayes' trading history.

Who are Verrica Pharmaceuticals' active insiders?

Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), Paul Manning (Director), and Ted White (CEO). Learn More on Verrica Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Verrica Pharmaceuticals?

During the last year, insiders at the sold shares 3 times. They sold a total of 62,245 shares worth more than $411,790.55. The most recent insider tranaction occured on March, 17th when insider Christopher G Hayes sold 4,315 shares worth more than $2,804.75. Insiders at Verrica Pharmaceuticals own 42.6% of the company. Learn More about insider trades at Verrica Pharmaceuticals.

Information on this page was last updated on 3/17/2025.

Christopher G. Hayes Insider Trading History at Verrica Pharmaceuticals

See Full Table

Christopher G. Hayes Buying and Selling Activity at Verrica Pharmaceuticals

This chart shows Christopher G Hayes's buying and selling at Verrica Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$2.81ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k$0$100kTotal Insider BuyingTotal Insider Selling

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals logo
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Read More

Today's Range

Now: $0.44
Low: $0.42
High: $0.49

50 Day Range

MA: $0.66
Low: $0.48
High: $0.74

2 Week Range

Now: $0.44
Low: $0.42
High: $11.41

Volume

608,897 shs

Average Volume

557,291 shs

Market Capitalization

$40.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44